Trial Profile

(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 29 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Docetaxel (Primary) ; Paclitaxel (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary) ; Trastuzumab emtansine (Primary)
Indications Advanced breast cancer; Carcinoma; Early breast cancer; HER2 positive breast cancer; Male breast cancer
Focus Therapeutic Use
Acronyms CompassHER2-pCR

Most Recent Events

27 May 2025 According to the REVEAL GENOMICS Media Release, company announced the presentation of data from this study at the 2025 ASCO Annual Meeting.
18 Apr 2025 Status changed from recruiting to active, no longer recruiting.
02 Mar 2023 Planned End Date changed from 28 Feb 2023 to 31 Dec 2038.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com